vimarsana.com
Home
Live Updates
MinervaX announces 72M EUR financing to advance development of novel vaccine against Group B Streptococcus : vimarsana.com
MinervaX announces 72M EUR financing to advance development of novel vaccine against Group B Streptococcus
/PRNewswire/ -- MinervaX ApS, a privately held Danish biotechnology company developing a novel vaccine against Group B Streptococcus (GBS), today announces the...
Related Keywords
Germany ,
South Africa ,
Wellington ,
New Zealand General ,
New Zealand ,
Paris ,
France General ,
France ,
Denmark ,
Copenhagen ,
Køavn ,
United Kingdom ,
Danish ,
Veronica Gambillara ,
Pureos Bioventures ,
Christian Thomsen ,
Groupb Strep International ,
Groupb Streptococcus ,
Lund University ,
European Union ,
European Medicines Agency ,
Groupb Strep ,
Impact Fund Novo Holdings ,
European Investment Bank ,
Trill Impact Ventures ,
European Investment ,
Novo Holdings ,
Sunstone Life Science Ventures ,
Wellington Partners ,
Sanofi Ventures ,
Adjuvant Capital ,
Chief Executive Officer ,
Bita Sehat ,
Senior Director ,
Senior Investment Director ,
Life Science ,
Groupb Strep Support ,
Impact House ,
Trill Impact ,
Swiss Based Pureos Partners ,
Climate Bank Roadmap ,
Innovfin Infectious Diseases Finance Facility ,
Minervax ,
vimarsana.com © 2020. All Rights Reserved.